Inhibitors of bacterial protein synthesis 1 Flashcards
Aminoglycosides
Amikacin Gentamicin Neomycin Streptomycin Tobramycin
Aminoglycosides administration
IV: Amikacin IV or Topical: Gentamicin and Tobramycin IM: Streptomycin Topical or Oral: Neomycin The amino group become protonated and ionized in body fluids, that is why they are poorly absorbed from the gut and must be administered parentally. Occasionally, aminoglycosides are administered orally to treat GI infections such as neonatal necrotizing enterocolitis. They are also administered topically to treat infections of the skin, mucous membranes, and ocular tissues.
Bacterial resistance to aminoglycosides
Primarily caused by inactivation of the drugs by bacterial enzymes that combine the drug with acetate, phosphate, or adenylate Also caused by decreased binding of the drugs to the 30S ribosomal subunit or to decreased uptake of the drugs by porins in bacterial membranes
Aminoglycosides - Advers effects
Most serious: Nephrotoxicity and Ototoxicity (vestibular and cochlear) Vestibular toxicity manifestations: Dizziness, impaired vision, nystagmus, vertigo, nausea, vomiting, and problems with postural balance and walking Cochlear toxicity manifestations: Tinnitus and hearing impairment and can lead to irreversible deafness Drug-induced renal failure (acute tubular necrosis, when they accumulate in proximal tubule cells) Glomerular toxicity High dose: respiratory paralysis (cuarare-like effect with neuromuscular blockade). Reversible by calcium gluconate or neostigmine. Hypersensitivity (infrequently)
Aminoglycosides tendency to cause cochlear or vestibular toxicity
Amikacin produces more cochlear toxicity (deafness), Gentamicin and streptomycin cause more vestibular toxicity. Tobramycin appears to cause similar degrees of cochlear and vestibular toxicity.
Most nephrotoxic aminoglycosides
Neomycin, Tobramycin and Gentamicin
Aminoglycosides - MoA
Bind 30S ribosomal subunit, interfering with initiation of protein synthesis and cause misreading of the genetic code Breakup of polysomes into nonfunctional monosomes
Amikacin - Clinical use
Strains of Proteus, Pseudomonas, Enterobacter, and Serratia Joint infections Intra-abdominal infections Meningitis Pneumonia Sepsis Urinary tract infections Strains of multidrug-resistant Mycobacterium tuberculosis, including streptomycin-resistant strains
Gentamicin - Clinical use
Mainly in severe infections (eg, sepsis and pneumonia) caused by gram-negative bacteria that are likely to be resistant to other drugs E. coli, Klebsiella, Enterobacteriae P. aeruginosa Serratia marcescens Proteus Acinetobacter In combination with a penicillin to treat serious enterococcal, staphylococcal, or viridans group streptococcal infections such as endocarditis
Tobramycin - Clinical use
The most active aminoglycoside against many strains of Pseudomonas aeruginosa Enterococcus faecalis
Streptomycin - Clinical use
Tuberculosis and infections caused by Yersinia pestis (plague) and Francisella tularensis (tularemia) Sometimes brucellosis Penicillin plus streptomycin is effective for enterococcal endocarditis and 2-week therapy of viridans streptococcal endocarditis.
Neomycin - Clinical use
Gram-positive and gram-negative and some mycobacteria Superficial infections Prevents Hepatic encephalopathy and Hypercholesterolemis
Paromomycin - Clincal use
has recently been shown to be effective against visceral leishmaniasis when given parenterally
Drugs that have similar properties as Neomycin
Kanamycin and Paromomycin
Tetracylines - MoA
Binds to 30 S ribosomal subunit, prevents addition of new amino acid to the nascent polypeptide chain. Bacteriostatic
Tetracyclines
Doxycycline Minocycline Tetracycline Tigecycline